Top Markets
Coin of the day
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rangering i aksjer #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Aksjekurs
$0.00162013
Sist synkronisert: 2025-01-03
Markedsverdi
$156.25K
Endring (1 dag)
0.36%
Endring (1 år)
0.00%
Land
SE
Handel Cyxone AB (publ) (CYXO)

Kategori

Utbytteavkastning for Cyxone AB (publ) (CYXO)
Cyxone AB (publ) (aksjesymbol: CYXO) sin utbytteavkastning (TTM) per 2022-12-31 er: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Cyxone AB (publ) (CYXO) fra 2015 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter